close

Clinical Trials

Date: 2011-09-05

Type of information:

phase: 2b

Announcement: conclusion of the phase

Company: Innovacell (Austria)

Product: ICES13

Action mechanism: autologous, individualized cell therapy

Disease: stress urinary incontinence

Therapeutic area:

Country: 4 undisclosed European states

Trial details:

Latest news: Innovacell has announced that the Phase IIb study of its cell therapy for the treatment of stress urinary incontinence ICES13, concludes successfully. This multi-centre Phase IIb study was conducted in 32 clinics in four European states. It embraced some 280 patients. This means the Phase III study can begin before the end of 2011 with the first results becoming available in the third quarter of 2012. Innovacel  already has the necessary permission from the health authorities of two states to carry out the study. Approval from the European Medicines Agency (EMA) is expected to be forthcoming in 2013.

Is general: Yes